서울제약

018680KOSDAQ

41.5 / 100

Reference Date: 2026-09-08

Financial Score17.0 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure7.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but PER raises overvaluation concerns. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Seoul Pharmaceutical focuses on developing improved new drugs and innovative drug delivery technologies, such as SmartFilm® Technology, to maintain competitiveness in the global pharmaceutical market. Key products like Ator, a cholesterol-lowering medication, drive growth, with sales reaching 53,580 million KRW and operating profit increasing by 26% in 2024. The company is expanding its market share in chronic disease areas and preparing to launch first-generic products ahead of patent expirations.

Number of Employees

132people

Average Salary

65.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

30.32Industry Average 15.000.0Point

2.0x industry avg (risky)

PBR

0.56Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

1.86Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

38.51Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼78.9% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 5.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 1,971Won52-week high 3,26552-week low 1,932

1-month return3.0Point

1m -0.35% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 3Negative 1

Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-28
Neutral임시주주총회결과2026-08-21
Neutral반기보고서 (2026.06)2026-08-14
Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14